Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.25 +3.5%	$0.27	$0.20 ▼ $1.48	$64.25M	2.18	1.66 million shs	459,962 shs
CTMX CytomX Therapeutics	$2.49 +0.4%	$2.03	$0.40 ▼ $3.10	$199.94M	2.05	2.19 million shs	755,783 shs
NNVC NanoViricides	$1.40 +0.7%	$1.43	$0.94 ▼ $2.55	$22.50M	0.91	237,727 shs	141,523 shs
UNCY Unicycive Therapeutics	$4.64 -0.1%	$6.27	$2.02 ▼ $11.00	$58.65M	1.89	265,849 shs	819,495 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+3.55%	+3.63%	-13.09%	-2.75%	-75.39%
CTMX CytomX Therapeutics	+0.40%	+7.79%	-6.04%	+446.53%	+91.54%
NNVC NanoViricides	+0.72%	+13.82%	-4.76%	+29.63%	-20.45%
UNCY Unicycive Therapeutics	-0.11%	-21.97%	-39.25%	-10.16%	-5.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.091 of 5 stars	3.1	5.0	0.0	1.1	0.8	0.0
CTMX CytomX Therapeutics	4.1594 of 5 stars	3.5	1.0	4.7	1.8	1.7	1.3
NNVC NanoViricides	1.1608 of 5 stars	0.0	5.0	0.0	3.9	0.0	0.0
UNCY Unicycive Therapeutics	3.1819 of 5 stars	3.8	3.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	438.51% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	114.19% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.50	Strong Buy	$60.00	1,194.50% Upside

Current Analyst Ratings Breakdown

Latest NNVC, ADAP, UNCY, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.37	N/A	N/A	$0.05 per share	5.02
CTMX CytomX Therapeutics	$138.10M	1.45	$0.36 per share	6.85	($0.01) per share	-249.00
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	5.19	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest NNVC, ADAP, UNCY, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
CTMX CytomX Therapeutics	N/A	1.73	1.73
NNVC NanoViricides	N/A	3.44	2.47
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CTMX CytomX Therapeutics	67.77%
NNVC NanoViricides	10.30%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CTMX CytomX Therapeutics	6.60%
NNVC NanoViricides	4.60%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

NNVC, ADAP, UNCY, and CTMX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY - Morningstar

July 3 at 12:12 AM | morningstar.comM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 2 at 10:00 AM | prnewswire.com

Unicycive hit with CRL on oxylanthanum carbonate NDA

July 1 at 3:25 PM | thepharmaletter.comT

Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

July 1 at 4:36 AM | theglobeandmail.com

Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance

June 30, 2025 | finance.yahoo.com

FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect

June 30, 2025 | fiercepharma.comF

Unicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemia

June 30, 2025 | msn.com

Unicycive stock falls after FDA issues Complete Response Letter

June 30, 2025 | investing.com

Unicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate Application

June 30, 2025 | marketwatch.com

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease ...

June 30, 2025 | finance.yahoo.com

Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing

June 30, 2025 | msn.com

INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC

June 30, 2025 | globenewswire.com

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 30, 2025 | globenewswire.com

Unicycive Therapeutics Inc News (UNCY) - Investing.com

June 24, 2025 | investing.com

Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?

June 20, 2025 | marketbeat.com

Unicycive Therapeutics Inc trading halted, news pending

June 18, 2025 | msn.com

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18, 2025 | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15, 2025 | marketbeat.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, ADAP, UNCY, and CTMX Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.25 +0.01 (+3.55%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$0.25 0.00 (0.00%)

As of 07/3/2025 04:44 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

CytomX Therapeutics NASDAQ:CTMX

$2.49 +0.01 (+0.40%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$2.49 0.00 (0.00%)

As of 07/3/2025 04:43 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

NanoViricides NYSE:NNVC

$1.40 +0.01 (+0.72%)

Closing price 07/3/2025 03:47 PM Eastern

Extended Trading

$1.42 +0.02 (+1.43%)

As of 07/3/2025 04:35 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Unicycive Therapeutics NASDAQ:UNCY

$4.64 -0.01 (-0.11%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$4.62 -0.02 (-0.43%)

As of 07/3/2025 04:59 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time